-
公开(公告)号:US20230235078A1
公开(公告)日:2023-07-27
申请号:US18176072
申请日:2023-02-28
发明人: Ningyan ZHANG , Zhiqiang AN , Hui DENG , Xiujie SUN , Rong LI
CPC分类号: C07K16/2896 , C12N15/63 , A61P35/00 , C07K2317/20 , C07K2317/565
摘要: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.
-
公开(公告)号:US20230130372A1
公开(公告)日:2023-04-27
申请号:US17757510
申请日:2020-12-17
发明人: Ningyan ZHANG , Zhiqiang AN , Hui DENG , Xiujie SUN , Rong LI
摘要: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer. Thus, in one aspect, the present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to DDR1. In certain embodiments, the antibody or antigen-binding fragment, when bound to DDR1, modulates the activity of DDR1, i.e., suppresses DDR1.
-
公开(公告)号:US20210349096A1
公开(公告)日:2021-11-11
申请号:US16321745
申请日:2017-07-27
发明人: Chengcheng ZHANG , Zhiqiang AN , Ningyan ZHANG , Mi DENG , Jaehyup KIM , Xun GUI
IPC分类号: G01N33/574 , G01N33/50 , G01N15/14 , G01N21/64
摘要: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.
-
公开(公告)号:US20220267415A1
公开(公告)日:2022-08-25
申请号:US17671837
申请日:2022-02-15
发明人: Zhiqiang KU , Xuping XIE , Paul HINTON , Ningyan ZHANG , Bruce KEYT , Dean NG , Stephen CARROLL , Pei-Yong SHI , Zhiqiang AN
摘要: This disclosure provides multimeric binding molecules that bind to SARS-CoV-2. This disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides that encode the multimeric binding molecules, and host cells that can produce the binding molecules. Further this disclosure provides methods of using the multimeric binding molecules, including methods for treating and preventing coronavirus disease 2019 (COVID-19).
-
公开(公告)号:US20190338026A1
公开(公告)日:2019-11-07
申请号:US16475223
申请日:2018-01-02
发明人: X. Charlene LIAO , Qiang LIU , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Chengcheng ZHANG , Mi DENG , Jingjing XIE
摘要: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
-
公开(公告)号:US20230399384A1
公开(公告)日:2023-12-14
申请号:US17996874
申请日:2021-04-22
发明人: Zhiqiang KU , Ningyan ZHANG , Zhiqiang AN , Xuping XIE , Pei-Yong SHI
CPC分类号: C07K16/1003 , A61P31/14 , C07K2317/76 , C07K2317/92 , C07K2317/34 , A61K2039/505
摘要: Provided herein are antibodies binding to Coronavirus S protein and the uses of the antibodies in detecting and treating Coronavirus infection, such as COVID-19.
-
公开(公告)号:US20230348586A1
公开(公告)日:2023-11-02
申请号:US18026696
申请日:2021-09-21
发明人: Phillipp E. SCHERER , Shangang ZHAO , Zhiqiang AN , Ningyan ZHANG
IPC分类号: C07K16/26 , A61K38/46 , A61K31/7088 , A61K38/22 , C12N15/113 , A61K38/26 , A61K39/395 , A61P3/04 , A61P35/02 , A61P35/00 , A61P9/00 , A61P1/16
CPC分类号: C07K16/26 , A61K38/465 , A61K31/7088 , A61K38/2264 , C12N15/1136 , A61K38/26 , A61K39/3955 , A61P3/04 , A61P35/02 , A61P35/00 , A61P9/00 , A61P1/16 , C12N2310/14 , C12N2310/531 , A61K2039/505
摘要: The present disclosure relates generally to therapeutic agents and related uses thereof, including, agents for reducing leptin in a patient or subject and methods of treatment thereof. The therapeutic agents can comprise (without limitation), an antibody or specific binding fragment thereof, a leptin antagonist, a leptin targeting antisense oligonucleotide, a leptin targeting small interfering RNA (siRNA), a leptin targeting short hairpin RNA (shRNA), and/or a gene editing composition directed to at least one target sequence of a leptin polynucleotide. The therapeutic agents can be used in various methods of treatment, including (without limitation), treating liver fibrosis, cancer, inducing or maintaining weight loss, reducing or preventing weight gain, and increasing insulin sensitivity, among others.
-
公开(公告)号:US20210179687A1
公开(公告)日:2021-06-17
申请号:US16762273
申请日:2018-11-06
发明人: Chengcheng ZHANG , Samuel JOHN , Heyu CHEN , Mi DENG , Xun GUI , Ningyan ZHANG , Zhiqiang AN
IPC分类号: C07K14/705 , A61K45/06 , A61P35/02 , C12N5/0783
摘要: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.
-
公开(公告)号:US20190031751A1
公开(公告)日:2019-01-31
申请号:US16075711
申请日:2017-02-06
发明人: Ningyan ZHANG , Zhiqiang AN , Anil K. SOOD
IPC分类号: C07K16/22 , A61P35/00 , A61K9/00 , C12N15/113
摘要: Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
公开(公告)号:US20230068663A1
公开(公告)日:2023-03-02
申请号:US17759800
申请日:2021-01-28
发明人: Zhiqiang AN , Ningyan ZHANG , Zhiqiang KU , Chengcheng ZHANG , Xiaoye XU , Heyu CHEN , JingJing XIE , Maria Jose COSTA , An SONG , X. Charlene LIAO
IPC分类号: C07K16/28 , A61K45/06 , A61K47/68 , A61P35/02 , A61K39/395 , G01N33/574
摘要: Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
-
-
-
-
-
-
-
-
-